|
||||||||||||||||||||||
|
|
Alternate Title Phase III Randomized Study of Percutaneous Isolated Hepatic Arterial Perfusion With Melphalan With Subsequent Venous Hemofiltration Versus Best Alternative Standard Treatment in Patients With Unresectable Liver Metastases Secondary to Ocular or Cutaneous Melanoma
Special Category: NCI Web site featured trial, NIH Clinical Center trial Trial Description Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving melphalan directly into the arteries around the tumor may kill more tumor cells. It is not yet known whether hepatic arterial infusion with melphalan is more effective than standard therapy in treating liver metastases due to melanoma. This randomized phase III trial is studying hepatic arterial infusion with melphalan to see how well it works compared to standard therapy in treating patients with unresectable liver metastases due to melanoma. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will be randomly assigned (have an equal chance of being placed) to one of two treatment groups. Patients in group one will undergo isolated hepatic infusion with melphalan. Treatment may repeat every 4 weeks for up to six courses. Patients in group two will receive standard therapy chosen by their doctor. Patients will undergo blood sample collection periodically for laboratory studies. After finishing treatment, patients will be evaluated periodically for 4 years and once a year thereafter. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations NCI - Center for Cancer Research
Related Information
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |